Alpha Cognition Inc. announced it will present new clinical insights on cholinesterase inhibitors and ZUNVEYL at the American Society of Consultant Pharmacists (ASCP) Annual Meeting, scheduled for October 23–25, 2025. This presentation aims to provide renewed, evidence-based guidance for clinicians, patients, and families.
The company recognizes that much of the product-specific knowledge regarding cholinesterase inhibitors has been lost since their introduction decades ago. With ZUNVEYL, Alpha Cognition seeks to re-examine these treatments and highlight its differentiated profile.
The ASCP Annual Meeting is a key forum for advancing safe and effective medication use for older adults across long-term, post-acute, and senior care settings. This presentation is a strategic effort to educate a critical audience for ZUNVEYL's market penetration.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.